Zanzalintinib for advanced thyroid cancer before surgery
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests a drug called zanzalintinib for people with advanced thyroid cancer that has spread nearby. The goal is to see if taking this pill before surgery can shrink the tumor and make it easier to remove.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of thyroid cancer (papillary, follicular, Hürthle cell, medullary without certain mutations, or poorly differentiated) that has spread to nearby areas or has come back as bulky disease.
- You need to be at least 18 years old.
- Your cancer must be considered moderate to very severe or difficult to remove (score 1 to 4 on a standard scale).
- You must be in fairly good health (able to do daily activities) with no rapid decline in the last 2 weeks.
- You must have adequate organ function (kidneys, liver, blood counts) as shown by blood and urine tests.
- You must agree to have a tumor biopsy before treatment (if at MD Anderson) and to have surgery if the tumor becomes removable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving treatment before surgery (neoadjuvant therapy) helps people with locally advanced thyroid cancer. It aims to shrink the tumor so surgery can be more successful.
This study tests a new oral medication called zanzalitinib, which may help slow the growth of advanced prostate cancer that has continued to spread despite hormone therapy and possibly chemotherapy. The goal is to see if the drug is safe and effective for men with this type of cancer.
This trial tests two drugs—zanzalintinib and nivolumab—given before surgery to shrink advanced or hard-to-remove kidney tumors. The goal is to make the tumor easier to remove and improve outcomes.
This trial tests a new drug, zanzalintinib, for people with adenoid cystic carcinoma that has come back or spread and can't be treated with local therapy. The drug may help slow or stop the cancer's growth.
This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.
This trial tests a new oral medication called zanzalintinib for adults with a rare type of tumor called pheochromocytoma or paraganglioma that has spread or cannot be removed with surgery. The goal is to see if this drug can slow or stop the tumor from growing, and to evaluate its safety.
Hear when a new Neoadjuvant Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.